Global Icotinib 麻豆原创 Research Report 2023

Publication ID:

PB510230692

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Icotinib听(trade name听Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.听
The global Icotinib market is projected to reach US$ 28 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 8.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Icotinib market research.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Icotinib market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Bette Pharma
Segment by Type
250mg
125mg
Segment by Application
Hospital
Drugs Store
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Icotinib report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, 麻豆原创 Channel and Customer Analysis
Chapter 8: 麻豆原创 Opportunities and Challenges
Chapter 9: 麻豆原创 Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Icotinib 麻豆原创 Overview
1.1 Product Overview and Scope of Icotinib
1.2 Icotinib Segment by Type
1.2.1 Global Icotinib 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 250mg
1.2.3 125mg
1.3 Icotinib Segment by Application
1.3.1 Global Icotinib 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Drugs Store
1.4 Global Icotinib 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Icotinib Revenue 2018-2029
1.4.2 Global Icotinib Sales 2018-2029
1.4.3 Global Icotinib 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Icotinib 麻豆原创 Competition by Manufacturers
2.1 Global Icotinib Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Icotinib Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Icotinib Average Price by Manufacturers (2018-2023)
2.4 Global Icotinib Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Icotinib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Icotinib, Product Type & Application
2.7 Icotinib 麻豆原创 Competitive Situation and Trends
2.7.1 Icotinib 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Icotinib Players 麻豆原创 Share by Revenue
2.7.3 Global Icotinib 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Icotinib Retrospective 麻豆原创 Scenario by Region
3.1 Global Icotinib 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Icotinib Global Icotinib Sales by Region: 2018-2029
3.2.1 Global Icotinib Sales by Region: 2018-2023
3.2.2 Global Icotinib Sales by Region: 2024-2029
3.3 Global Icotinib Global Icotinib Revenue by Region: 2018-2029
3.3.1 Global Icotinib Revenue by Region: 2018-2023
3.3.2 Global Icotinib Revenue by Region: 2024-2029
3.4 North America Icotinib 麻豆原创 Facts & Figures by Country
3.4.1 North America Icotinib 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Icotinib Sales by Country (2018-2029)
3.4.3 North America Icotinib Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Icotinib 麻豆原创 Facts & Figures by Country
3.5.1 Europe Icotinib 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Icotinib Sales by Country (2018-2029)
3.5.3 Europe Icotinib Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Icotinib 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Icotinib 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Icotinib Sales by Country (2018-2029)
3.6.3 Asia Pacific Icotinib Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Icotinib 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Icotinib 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Icotinib Sales by Country (2018-2029)
3.7.3 Latin America Icotinib Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Icotinib 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Icotinib 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Icotinib Sales by Country (2018-2029)
3.8.3 Middle East and Africa Icotinib Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Icotinib Sales by Type (2018-2029)
4.1.1 Global Icotinib Sales by Type (2018-2023)
4.1.2 Global Icotinib Sales by Type (2024-2029)
4.1.3 Global Icotinib Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Icotinib Revenue by Type (2018-2029)
4.2.1 Global Icotinib Revenue by Type (2018-2023)
4.2.2 Global Icotinib Revenue by Type (2024-2029)
4.2.3 Global Icotinib Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Icotinib Price by Type (2018-2029)
5 Segment by Application
5.1 Global Icotinib Sales by Application (2018-2029)
5.1.1 Global Icotinib Sales by Application (2018-2023)
5.1.2 Global Icotinib Sales by Application (2024-2029)
5.1.3 Global Icotinib Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Icotinib Revenue by Application (2018-2029)
5.2.1 Global Icotinib Revenue by Application (2018-2023)
5.2.2 Global Icotinib Revenue by Application (2024-2029)
5.2.3 Global Icotinib Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Icotinib Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bette Pharma
6.1.1 Bette Pharma Corporation Information
6.1.2 Bette Pharma Description and Business Overview
6.1.3 Bette Pharma Icotinib Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bette Pharma Icotinib Product Portfolio
6.1.5 Bette Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Icotinib Industry Chain Analysis
7.2 Icotinib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Icotinib Production Mode & Process
7.4 Icotinib Sales and 麻豆原创ing
7.4.1 Icotinib Sales Channels
7.4.2 Icotinib Distributors
7.5 Icotinib Customers
8 Icotinib 麻豆原创 Dynamics
8.1 Icotinib Industry Trends
8.2 Icotinib 麻豆原创 Drivers
8.3 Icotinib 麻豆原创 Challenges
8.4 Icotinib 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Bette Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.